Amicus Therapeutics (NASDAQ:FOLD) Research Coverage Started at Citigroup

Citigroup began coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research note issued to investors on Wednesday, Marketbeat Ratings reports. The firm issued a buy rating and a $17.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on FOLD. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. lifted their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Needham & Company LLC upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Thursday, September 18th. Finally, The Goldman Sachs Group lifted their price objective on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.36.

Amicus Therapeutics Trading Up 30.4%

NASDAQ FOLD opened at $14.20 on Wednesday. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $14.36. The company has a 50-day moving average of $9.48 and a 200-day moving average of $7.82. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The company has a market cap of $4.38 billion, a P/E ratio of -354.81 and a beta of 0.46.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. During the same period last year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, equities analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current year.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Jeff Castelli sold 76,158 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $10.16, for a total value of $773,765.28. Following the completion of the sale, the insider owned 439,318 shares of the company’s stock, valued at $4,463,470.88. This trade represents a 14.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total transaction of $846,276.36. Following the transaction, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. The trade was a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 319,808 shares of company stock valued at $3,293,653. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in Amicus Therapeutics in the 3rd quarter worth $43,000. Tudor Investment Corp ET AL increased its position in shares of Amicus Therapeutics by 5.9% during the third quarter. Tudor Investment Corp ET AL now owns 168,984 shares of the biopharmaceutical company’s stock worth $1,332,000 after acquiring an additional 9,487 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Amicus Therapeutics by 36.3% in the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,246 shares in the last quarter. Swiss Life Asset Management Ltd acquired a new position in shares of Amicus Therapeutics in the third quarter worth about $83,000. Finally, CIBC Bancorp USA Inc. purchased a new position in Amicus Therapeutics in the third quarter valued at about $234,000.

Key Headlines Impacting Amicus Therapeutics

Here are the key news stories impacting Amicus Therapeutics this week:

• Positive Sentiment: BioMarin to acquire Amicus for ~$4.8B ($14.50 per share), citing complementary marketed products (Galafold, Pombiliti + Opfolda), $599M of recent revenue and expectations the deal will be accretive to non‑GAAP EPS within 12 months — this provides a clear exit price and strategic rationale that pushed the stock up. Article Title
• Positive Sentiment: BioMarin’s press release emphasizes revenue upside from bringing Amicus products into BioMarin’s global footprint and resolving pending patent litigation on Galafold — details that support the acquisition valuation and near-term revenue accretion view. Article Title
• Neutral Sentiment: Trading was temporarily halted pre-market for “news pending,” then resumed around the acquisition announcement — a procedural sign the market treated the item as material. (Trading halt noted in market alerts.)
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a “neutral” rating with a $14.50 price target (roughly in line with the deal price), and Needham reiterated a “hold” — analyst stances imply limited upside beyond the announced offer price absent a competing bidder. Article Title
• Negative Sentiment: Two investor‑rights firms (Halper Sadeh LLC and The Ademi Firm) announced investigations into whether the $14.50 per‑share sale is fair to Amicus shareholders — litigation or proxy fights could delay closing, pressure timing, or open the door to a higher bid/renegotiation, increasing deal execution risk. Article Title
• Negative Sentiment: Insider selling disclosures (including recent sales by the CEO and another officer) surfaced in filings earlier this week — while not unusual, these sales add a note of caution for some investors evaluating management alignment ahead of the deal. Article Title

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.